BEIJING LUZHU BIOTECHNOLOGY CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.3 HKD | -0.82% |
|
-2.41% | -18.73% |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 5,502 | 4,600 | - | - |
| Enterprise Value (EV) 1 | 5,502 | 4,101 | 4,336 | 4,611 |
| P/E ratio | -21.7 x | -14.1 x | -13.7 x | -17.9 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | 4,035 x | 45.9 x | 14.8 x |
| EV / Revenue | - | 3,598 x | 43.3 x | 14.9 x |
| EV / EBITDA | - | -13.4 x | -17.6 x | -54.3 x |
| EV / FCF | - | -15.3 x | -17.8 x | -20 x |
| FCF Yield | - | -6.55% | -5.62% | -5.01% |
| Price to Book | - | 7.18 x | 13.9 x | 52.1 x |
| Nbr of stocks (in thousands) | 202,449 | 202,449 | - | - |
| Reference price 2 | 27.18 | 22.72 | 22.72 | 22.72 |
| Announcement Date | 3/15/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | 1.14 | 100.2 | 310.3 |
| EBITDA 1 | - | - | -305 | -246 | -85 |
| EBIT 1 | - | -222 | -314 | -313.5 | -229 |
| Operating Margin | - | - | -27,543.86% | -312.81% | -73.8% |
| Earnings before Tax (EBT) 1 | - | -249.4 | -326 | -336 | -256 |
| Net income 1 | -725.2 | -249.4 | -326 | -336 | -256 |
| Net margin | - | - | -28,596.49% | -335.26% | -82.5% |
| EPS 2 | - | -1.250 | -1.610 | -1.661 | -1.266 |
| Free Cash Flow 1 | - | - | -268.5 | -243.5 | -231 |
| FCF margin | - | - | -23,552.63% | -242.96% | -74.44% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 4/24/23 | 3/15/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 S2 |
|---|---|
| Net sales | - |
| EBITDA | - |
| EBIT | - |
| Operating Margin | - |
| Earnings before Tax (EBT) 1 | -170 |
| Net income 1 | -170 |
| Net margin | - |
| EPS | - |
| Dividend per Share | - |
| Announcement Date | 3/15/24 |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 11 |
| Net Cash position 1 | - | - | 499 | 264 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | -0.1294 x |
| Free Cash Flow 1 | - | - | -269 | -244 | -231 |
| ROE (net income / shareholders' equity) | - | - | -41.6% | -97.6% | -1,465% |
| ROA (Net income/ Total Assets) | - | - | - | -23.5% | - |
| Assets 1 | - | - | - | 1,430 | - |
| Book Value Per Share 2 | - | - | 3.160 | 1.630 | 0.4400 |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | - | 80 | 43 | 74 |
| Capex / Sales | - | - | 7,017.54% | 42.91% | 23.85% |
| Announcement Date | 4/24/23 | 3/15/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
22.72
CNY
Average target price
27.73
CNY
Spread / Average Target
+22.03%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -18.73% | 635M | |
| -1.62% | 89.22B | |
| +2.24% | 40.49B | |
| -12.97% | 32.79B | |
| +63.75% | 26.23B | |
| -20.71% | 14.52B | |
| -7.31% | 13.09B | |
| -42.60% | 11.6B | |
| -12.64% | 11.5B | |
| +5.47% | 8.82B |
- Stock Market
- Equities
- 2480 Stock
- Financials Beijing Luzhu Biotechnology Co., Ltd.
